Coagulopathy and thrombocytopenia

12 min read Last updated April 8, 2026

Surgical approach (not a single operation; typical surgical responses to bleeding/coagulopathy)

  • Control bleeding source early: direct pressure, clamp/ligate, cautery, topical haemostats, packing
    • Damage control surgery if unstable: rapid haemorrhage control + temporary closure; definitive surgery later
    • Minimise ongoing blood loss: tourniquet (limb), pelvic binder, tamponade (e.g. uterine balloon), endoscopic haemostasis where appropriate
  • Correct reversible surgical contributors: hypothermia, acidosis, dilution, ongoing contamination/sepsis
    • Request early major haemorrhage protocol (MHP) and point-of-care coagulation testing (TEG/ROTEM) where available
  • Interventional radiology alternatives: embolisation (pelvis, postpartum haemorrhage, GI bleed), stenting

Anaesthetic management (context-dependent: bleeding/coagulopathy rather than a single procedure)

  • Type of anaesthesia: usually GA for active bleeding/major surgery; regional/neuraxial only if coagulation status acceptable and stable
    • Avoid neuraxial techniques in significant coagulopathy or severe thrombocytopenia; follow local/ASRA/ESAIC guidance and haematology advice
  • Airway: ETT often preferred (aspiration risk, need for controlled ventilation, prolonged surgery, massive transfusion); SGA only for low-risk, short cases with stable coagulation
  • Duration: variable (minutes for damage control to many hours for definitive surgery); plan for prolonged resuscitation and re-look surgery
  • Pain: depends on surgery; anticipate high pain for laparotomy/orthopaedics—use multimodal analgesia; consider regional blocks only if safe
    • If neuraxial contraindicated: consider IV opioids, ketamine, lidocaine infusion (selected), TAP/rectus sheath blocks if coagulation acceptable for fascial plane blocks
  • Monitoring/Access: 2 large-bore IVs, arterial line early, consider central access; active warming; urinary catheter; frequent labs/POC testing
    • Have rapid infuser/Level 1, blood warmer, pressure bags; calcium replacement plan
  • Resuscitation strategy: balanced blood components guided by MHP + TEG/ROTEM; permissive hypotension only in selected trauma without TBI
    • Early tranexamic acid (TXA) where indicated (e.g. trauma within 3 h; postpartum haemorrhage)

Definitions and classification

  • Coagulopathy: impaired haemostasis due to abnormalities of platelets, coagulation factors, fibrinogen, or fibrinolysis → bleeding and/or thrombosis
  • Thrombocytopenia: platelet count <150 × 10^9/L (severity: mild 100–150, moderate 50–99, severe <50; critical <20)
  • Primary vs secondary haemostasis
    • Primary: platelet number/function + vWF → mucocutaneous bleeding (epistaxis, petechiae, menorrhagia)
    • Secondary: coagulation factors/fibrin → deep tissue bleeding (haemarthroses, muscle haematoma, delayed re-bleeding)

Causes (high-yield differentials)

  • Dilutional/consumptive (perioperative/critical care): massive haemorrhage, trauma-induced coagulopathy, DIC, liver failure, sepsis, hypothermia, acidosis, hypocalcaemia
  • Drug-related
    • Anticoagulants: warfarin, DOACs (apixaban/rivaroxaban/edoxaban; dabigatran), heparins
    • Antiplatelets: aspirin, clopidogrel/prasugrel/ticagrelor; GP IIb/IIIa inhibitors
    • Other: valproate (platelet dysfunction), SSRIs (platelet serotonin), antibiotics (rare), chemotherapy
  • Thrombocytopenia mechanisms
    • Reduced production: marrow failure, chemotherapy, B12/folate deficiency, alcohol, sepsis
    • Increased destruction/consumption: ITP, TTP/HUS, DIC, sepsis, HIT, immune drug-induced
    • Sequestration: hypersplenism (portal HTN, liver disease)
    • Dilution: massive transfusion/fluids
    • Pseudothrombocytopenia: EDTA-related platelet clumping (repeat in citrate tube; blood film)
  • Inherited bleeding disorders (important perioperative)
    • von Willebrand disease (most common): platelet adhesion defect + low factor VIII; mucosal bleeding
    • Haemophilia A (VIII) / B (IX): deep bleeding; prolonged APTT

Assessment: history and examination

  • Bleeding history: easy bruising, epistaxis, gum bleeding, menorrhagia, postpartum bleeding, surgical/dental bleeding, delayed re-bleeding
  • Drug history: anticoagulants/antiplatelets, herbal supplements (e.g. ginkgo), recent antibiotics, chemotherapy
  • Systemic disease: liver disease, renal failure (uraemic platelet dysfunction), sepsis, malignancy, autoimmune disease, pregnancy (HELLP)
  • Examination: petechiae/purpura (platelet), ecchymoses, mucosal bleeding, haemarthrosis (factor deficiency), jaundice/hepatosplenomegaly

Investigations: what they mean and limitations

  • FBC: platelet count; Hb trend; blood film (schistocytes in TTP/DIC; clumping in pseudo-thrombocytopenia)
  • PT/INR: extrinsic/common pathway (VII, X, V, II, fibrinogen); sensitive to warfarin, liver disease, vitamin K deficiency
  • APTT: intrinsic/common (XII, XI, IX, VIII, X, V, II, fibrinogen); prolonged in heparin, haemophilia, lupus anticoagulant (thrombosis risk)
  • Fibrinogen (Clauss): low in DIC/massive haemorrhage; key target in obstetric haemorrhage
  • D-dimer/FDP: elevated in DIC/lysis; non-specific
  • TEG/ROTEM: whole-blood viscoelastic testing—faster functional assessment; helps target fibrinogen vs platelets vs factors vs fibrinolysis
    • Limitations: may miss specific platelet drug effects; interpretation requires training; results depend on temperature/haematocrit
  • Renal/liver function, calcium, ABG (pH/lactate), temperature: correctable drivers of coagulopathy

Key perioperative targets (pragmatic)

  • Temperature: aim normothermia (hypothermia impairs platelet function and enzyme kinetics)
  • pH: treat acidosis (reduces coagulation factor activity; worsens shock)
  • Ionised calcium: maintain (citrate in transfused blood chelates Ca2+ → hypotension/coagulopathy)
  • Fibrinogen: early replacement if low/bleeding (often first factor to fall in major haemorrhage)
  • Platelets: maintain adequate count for procedure/bleeding risk (see thresholds below)

Platelet thresholds (exam-friendly, typical practice; confirm local policy)

  • Prophylactic platelet transfusion (non-bleeding): often <10 × 10^9/L (or <20 with additional risk factors); specialist-led
  • Most surgery / active bleeding: aim ≥50 × 10^9/L
  • Major surgery with high bleeding risk (e.g. neurosurgery, posterior eye surgery): aim ≥100 × 10^9/L
  • Neuraxial anaesthesia: depends on context and trend; commonly ≥75–80 × 10^9/L for epidural/spinal if stable and no other coagulopathy; obstetrics may accept lower in selected cases with senior decision-making
    • Consider platelet trend, cause (ITP vs pre-eclampsia/HELLP), other coag tests, clinical bleeding, and availability of urgent imaging/neurosurgery

Management of coagulopathy in major haemorrhage (principles)

  • Activate MHP early; communicate with lab and blood bank; assign roles; use checklists
  • Balanced component therapy while awaiting results (local packs often approximate RBC:FFP:platelets ~1:1:1) then switch to goal-directed therapy (TEG/ROTEM/labs)
  • Fibrinogen replacement: cryoprecipitate or fibrinogen concentrate (if available) when fibrinogen low or ROTEM suggests low clot amplitude due to fibrinogen deficit
  • FFP: replaces multiple factors; used for bleeding with prolonged PT/APTT or as part of MHP; avoid using FFP solely to 'correct INR' in non-bleeding unless procedure requires
  • Platelets: treat thrombocytopenia or platelet dysfunction with bleeding; consider additional platelets if on antiplatelet agents and life-threatening bleeding (specialist advice)
  • TXA: early in trauma (within 3 hours) and postpartum haemorrhage; consider in other major bleeding per local policy
  • Avoid iatrogenesis: excessive crystalloids (dilution), hypothermia, high chloride acidosis; ensure warming and calcium replacement

Reversal of anticoagulants (high-yield perioperative)

  • Warfarin: vitamin K (IV for urgent reversal) + 4-factor PCC for major bleeding/urgent surgery; FFP if PCC unavailable
  • Unfractionated heparin: protamine (titrate to dose/time; risk hypotension/anaphylactoid reactions)
  • LMWH: protamine partially reverses (best within hours of dose); consider time since last dose and renal function
  • Dabigatran: idarucizumab for life-threatening bleeding/urgent surgery; dialysis can remove dabigatran if needed
  • Factor Xa inhibitors (apixaban/rivaroxaban/edoxaban): andexanet alfa where available for life-threatening bleeding; otherwise 4-factor PCC often used off-label per local guidance
  • Antiplatelets: no specific reversal for aspirin/P2Y12; options in major bleeding include platelet transfusion (timing matters), TXA, DDAVP in selected cases; seek haematology/cardiology input if recent stent

Specific perioperative thrombocytopenia syndromes (recognise and act)

  • HIT (heparin-induced thrombocytopenia): platelet fall typically 5–14 days after heparin (or sooner with prior exposure) + thrombosis risk; stop all heparin and use non-heparin anticoagulant (specialist-led)
    • Do NOT give platelets routinely unless life-threatening bleeding or urgent surgery (may worsen thrombosis risk)
  • TTP/HUS: microangiopathic haemolysis + thrombocytopenia ± neuro/renal; urgent plasma exchange; avoid platelet transfusion unless life-threatening bleeding
  • ITP: isolated thrombocytopenia; treat with steroids/IVIG for urgent procedures; platelet transfusion often short-lived but can be used with IVIG/steroids if emergency surgery/bleeding
  • DIC: consumption of platelets and factors (low fibrinogen, prolonged PT/APTT, high D-dimer); treat cause + supportive blood components guided by bleeding and labs/TEG
  • Liver disease: reduced synthesis of pro/anti-coagulants; INR may not reflect bleeding risk; consider TEG/ROTEM; correct fibrinogen/platelets if bleeding or before high-risk procedures
  • Uraemia: platelet dysfunction; consider dialysis, DDAVP, TXA (selected), and optimise anaemia

Neuraxial and regional anaesthesia considerations

  • Assess: platelet count and trend, coagulation tests, drug timing (DOAC/LMWH), liver/renal disease, clinical bleeding, and procedural risk (epidural > spinal)
  • If neuraxial performed: minimise traumatic attempts; senior operator; document decision-making; plan postoperative neuro checks and escalation for back pain/weakness/bladder dysfunction
  • Peripheral nerve blocks: compressible superficial blocks generally lower risk than neuraxial; deep plexus blocks (lumbar plexus, paravertebral) carry higher bleeding risk—treat similarly to neuraxial in anticoagulated patients

Practical approach to the bleeding perioperative patient (structured)

  • A–E resuscitation + haemorrhage control; call for help early (senior anaesthetist, surgeon, haematology, transfusion lab)
  • Send bloods early and repeatedly: FBC, PT/INR, APTT, fibrinogen, group & screen/crossmatch, ABG with Ca2+, lactate; use TEG/ROTEM if available
  • Start MHP if criteria met; use rapid infuser/warming; give TXA when indicated; replace calcium
  • Targeted component therapy: fibrinogen first if low; then platelets and plasma guided by results; consider PCC for warfarin/DOAC-related bleeding per policy
  • Reassess continuously: surgical field bleeding, haemodynamics, temperature, acid-base, ionised calcium, coagulation results; avoid over-transfusion and monitor for complications
You are called to theatre for ongoing surgical bleeding. Outline your immediate anaesthetic priorities and how you would manage suspected coagulopathy.

Aim: stabilise physiology, stop bleeding, correct coagulopathy with a structured approach.

  • Call for help and activate major haemorrhage protocol early; allocate roles; inform blood bank and haematology
  • A–E: secure airway (often ETT), 100% O2, controlled ventilation; treat shock with blood products rather than large volumes of crystalloid
  • Access/monitoring: 2 large-bore IVs, arterial line, consider central line; rapid infuser and blood warmer; active warming
  • Investigations: FBC, PT/INR, APTT, fibrinogen, group & crossmatch, ABG including ionised Ca2+, lactate; TEG/ROTEM if available
  • Treat reversible drivers: hypothermia, acidosis, hypocalcaemia; maintain perfusion and oxygen delivery
  • Blood components: balanced transfusion initially then goal-directed; early fibrinogen replacement if low; platelets if low/bleeding; plasma for factor deficiency
  • Adjuncts: TXA when indicated; consider anticoagulant reversal (vit K/PCC, protamine, specific DOAC antidotes) based on history and urgency
A patient has platelets 45 × 10^9/L and needs emergency laparotomy for perforation. What is your plan regarding platelets and anaesthetic technique?

Emergency high-risk surgery + likely sepsis/consumption → prioritise GA and haemostatic optimisation.

  • Choose GA with ETT (aspiration risk, sepsis, potential haemodynamic instability); avoid neuraxial
  • Aim platelet count ≥50 × 10^9/L for major surgery; transfuse platelets if bleeding or prior to incision depending on urgency and cause
  • Send coagulation labs and fibrinogen; consider TEG/ROTEM; treat sepsis physiology (warming, calcium, acid-base)
  • If thrombocytopenia is due to DIC/sepsis, expect ongoing consumption: repeat counts and give further platelets guided by bleeding and results
Discuss the causes of thrombocytopenia in the perioperative period and how you would distinguish them.

Use mechanism-based categories and time course; confirm with repeat testing and film.

  • Reduced production: marrow suppression/chemo, B12/folate deficiency, alcohol—typically chronic; other cell lines may be low
  • Increased destruction: ITP (isolated), drug-induced immune, HIT (timing 5–14 days + thrombosis), TTP (neuro/renal + schistocytes)
  • Consumption: DIC (prolonged PT/APTT, low fibrinogen, high D-dimer), sepsis/trauma
  • Sequestration: hypersplenism (liver disease, portal HTN) with splenomegaly
  • Dilutional: massive transfusion/large fluid volumes
  • Pseudothrombocytopenia: EDTA clumping—repeat in citrate tube and check film
How do PT/INR and APTT relate to the coagulation cascade, and what are their limitations in predicting bleeding?

They measure plasma-based clot initiation, not whole-blood haemostasis.

  • PT/INR: extrinsic/common pathway; sensitive to factor VII and warfarin; prolonged in liver disease/vit K deficiency
  • APTT: intrinsic/common; prolonged in heparin, haemophilia, inhibitors (e.g. lupus anticoagulant)
  • Limitations: do not assess platelet function, vWF, fibrinolysis, clot strength; poor correlation with bleeding in liver disease; affected by sampling/temperature
  • Viscoelastic tests (TEG/ROTEM) provide functional whole-blood information and can guide targeted therapy
A trauma patient is cold, acidotic and bleeding. Explain how hypothermia, acidosis and hypocalcaemia worsen coagulopathy and what you will do.

This is the lethal triad/diamond concept: physiology drives coagulopathy.

  • Hypothermia: impairs platelet function and slows enzymatic reactions of coagulation factors → weak clot
  • Acidosis: reduces activity of coagulation enzymes and worsens haemodynamics
  • Hypocalcaemia: citrate from transfused blood chelates Ca2+ (required for multiple coagulation steps) → hypotension and coagulopathy
  • Management: active warming, warmed fluids/blood, minimise exposure; restore perfusion and ventilation; monitor and replace ionised calcium; use MHP and targeted components
Outline a practical approach to managing warfarin-associated major bleeding requiring emergency surgery.

Reverse quickly and definitively while resuscitating and controlling bleeding.

  • Resuscitate and control bleeding; activate MHP if needed; send coagulation tests
  • Give IV vitamin K for sustained reversal
  • Give 4-factor PCC for rapid INR correction in major bleeding/urgent surgery (dose per INR/weight/local policy)
  • If PCC unavailable: consider FFP (slower, larger volumes) and manage volume overload risk
  • Recheck INR/TEG and clinical bleeding; avoid overcorrection and consider thrombosis risk post-op
A patient on apixaban presents with intracranial haemorrhage. What reversal options exist and what factors influence your choice?

Life-threatening bleeding: consider specific antidote if available; otherwise PCC-based strategies per policy.

  • Assess last dose timing, renal function, interacting drugs; send anti-Xa level if available (do not delay treatment in critical bleed)
  • Andexanet alfa may be used where available for life-threatening factor Xa inhibitor bleeding (institutional criteria apply)
  • If andexanet not available/appropriate: 4-factor PCC often used off-label per local guidance
  • Supportive care: neurosurgical involvement, BP control, avoid hypothermia/acidosis; consider TXA per local protocol
Explain the role of fibrinogen in major haemorrhage and how you replace it.

Fibrinogen is crucial for clot formation and platelet aggregation; it can fall early.

  • Low fibrinogen is associated with worse bleeding; particularly important in obstetric haemorrhage and trauma
  • Measure Clauss fibrinogen and/or use ROTEM fibrin-based assays to identify deficiency
  • Replace with cryoprecipitate or fibrinogen concentrate (if available); recheck levels and clinical response
You are asked to site an epidural for laparotomy. Platelets are 78 × 10^9/L, stable over 48 hours, normal PT/APTT, no bleeding history. How would you approach this decision?

Neuraxial decision is individualised: balance benefits vs risk of epidural haematoma.

  • Confirm cause and trend; exclude additional coagulopathy (liver disease, DIC), and review drugs (LMWH/DOAC timing)
  • Discuss with surgical team and patient; consider alternatives (IV PCA, fascial plane blocks) if risk unacceptable
  • If proceeding: senior operator, minimise attempts/trauma, document rationale; plan post-op neuro observations and clear escalation pathway
  • Consider that epidural catheter removal is also a risk point—plan timing with anticoagulant dosing and platelet monitoring
Describe heparin-induced thrombocytopenia (HIT) and its perioperative implications.

HIT is a prothrombotic immune complication of heparin exposure.

  • Features: platelet fall >50% typically 5–14 days after heparin (or rapid with recent exposure), thrombosis, skin necrosis; bleeding is less prominent
  • Immediate management: stop all heparin (including flushes); use alternative anticoagulation (specialist-led); send HIT testing
  • Avoid routine platelet transfusion unless life-threatening bleeding/urgent surgery
  • Perioperative planning: anticoagulation strategy for CPB/vascular procedures requires haematology/cardiac anaesthesia input
A patient with liver disease has INR 2.2 but is not bleeding. Does this predict bleeding risk and should you correct it before a procedure?

INR in liver disease is an imperfect marker; haemostasis may be 'rebalanced'.

  • INR reflects reduced procoagulant factors but does not account for reduced anticoagulant factors (protein C/S, antithrombin) or platelet/vWF changes
  • Bleeding risk depends on procedure, platelet count/function, fibrinogen, portal HTN, and clinical bleeding history
  • Avoid reflex FFP to correct INR in non-bleeding patients; consider TEG/ROTEM and correct specific deficits (e.g. fibrinogen/platelets) for high-risk procedures

0 comments